| 翻訳と辞書 |
TAS-108
TAS-108, also known as SR16234, is a drug discovered by Masato Tanabe and under development by SRI International and Taiho Pharmaceutical. It is a steroid hormone that has shown signs of treating and preventing breast cancer, even in patients where tamoxifen has failed.〔(【引用サイトリンク】title=Alumni Hall of Fame 2004: Masato Tanabe )〕〔(【引用サイトリンク】title=Novel Anti-Angiogenic Agents for Breast Cancer Therapy )〕
==Development==
Masato Tanabe's team at SRI has focused on the development of steroid hormones. A compound discovered in a previous SRI contract from the National Institute of Health showed potential – it acted like "anti-estrogen" in the breasts and uterus but like normal estrogen elsewhere in the body, and was more "tissue-selective". A contract was proposed to Taiho Pharmaceutical in July 1996, and within six years and slightly under $3 million (an unusually short amount of time), two new drugs were discovered and tested on people (particularly people for which tamoxifen has failed): SR16234 and SR16287.〔
The first of those, SR16234, also inhibited the growth of blood vessels angiogenesis and accelerated the death of cancer cells apoptosis and thus was particularly well suited to be an anti-cancer drug.〔 As of August 2010, the drug had been through five Phase I and two Phase II studies,〔(【引用サイトリンク】title=TAS-108: A Better Anti-Estrogen Drug for Treating Breast Cancer )〕 and Phase III studies are being planned.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「TAS-108」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|